Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Report 2026

Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Overview

• Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment market size has reached to $1.34 billion in 2025 • Expected to grow to $1.86 billion in 2030 at a compound annual growth rate (CAGR) of 6.9% • Growth Driver: Increase In The Number Of Prostate Cancer In Benign Prostatic Hyperplasia Market • Market Trend: Shift Toward Outpatient, Low-Invasiveness Procedures Supporting Market Evolution • North America was the largest region in 2025 and Western Europe is the fastest growing region.

What Is Covered Under Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market?

Benign prostatic hyperplasia or benign prostatic hypertrophy is a condition of prostate gland enlargement which causes blockade of urethra, the tube that carries urine from the bladder. The main products in the benign prostatic hyperplasia (BPH) treatment devices and equipment market are resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents, and implants. A resectoscope is an endoscope that is used for surgeries on the uterus, prostate, bladder, or urethra. The device helps in extracting tissue for biopsy, removing growths, or ablating diseased or damaged tissue. The various procedure types are transurethral needle ablation (TUNA), transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), transurethral microwave thermotherapy (TUMT), laser surgery, and others. The various end-users involved are hospitals, ambulatory surgical centres (ASC), clinics, homes.

What Is The Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Growth Forecast?

The benign prostatic hyperplasia (bph) treatment devices and equipment market size is expected to see strong growth in the next few years. It will grow to $1.86 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to increasing aging male population, rising preference for minimally invasive therapies, expansion of outpatient urology clinics, growing adoption of laser and implant-based treatments, increasing focus on reduced hospital stay. Major trends in the forecast period include increasing adoption of minimally invasive bph treatment devices, rising use of laser-based prostate therapies, growing demand for implant-based treatment options, expansion of office-based bph procedures, enhanced focus on patient comfort and recovery.

Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Segmentation

1) By Product: Resectoscopes, Radiofrequency Ablation Device, Urology Lasers, Prostatic Stents, Implants 2) By Procedure Type: Transurethral Needle Ablation (TUNA), Transurethral Resection Of Prostate (TURP), Transurethral Incision Of Prostate (TUIP), Transurethral Microwave Thermotherapy (TUMT), Laser Surgery, Other Procedure Types 3) By End-User: Hospitals, Ambulatory Surgical Centres (ASC), Clinics, Specialty Urology Centers Subsegments: 1) By Resectoscopes: Bipolar Resectoscopes, Monopolar Resectoscopes, High-Performance Resectoscopes 2) By Radiofrequency Ablation Device: Single-Needle Radiofrequency Ablation, Multi-Needle Radiofrequency Ablation 3) By Urology Lasers: Holmium Lasers, Diode Lasers, Green Light Lasers 4) By Prostatic Stents: Temporary Prostatic Stents, Permanent Prostatic Stents 5) By Implants: Prostatic Urethral Lift (PUL) Implants, Balloon-Expandable Stents, Permanent Implants for BPH Treatment

What Is The Driver Of The Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market?

The increase in the number of prostate cancer cases is anticipated to drive the growth of the benign prostatic hyperplasia market going forward. Prostate cancer refers to a type of cancer that develops in the prostate gland, which is a small, walnut-sized gland located just below the bladder in men. the increase in prostate cancer cases often results in a higher number of older men seeking medical attention for prostate-related issues. This leads to the identification and management of benign prostatic hyperplasia. For instance, in February 2023, according to the American Society of Clinical Oncology (ASCO), a US-based professional organization that publishes patient information on the cancer.net website, there were an estimated 288,300 men in the United States with prostate cancer in 2023, and there were 268,490 new cases and 34,500 deaths from prostate cancer in 2022. Therefore, the increase in the number of prostate cancer cases is driving the growth of the benign prostatic hyperplasia market.

Key Players In The Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market

Major companies operating in the benign prostatic hyperplasia (bph) treatment devices and equipment market are Karl Storz, Lumenis Ltd., Olympus Corporation, Urologix LLC, Boston Scientific Inc., NeoTract Inc., OmniGuide Inc., ProArc Medical Ltd., Urotech Devices, Prostalund Operations AB, NxThera Inc., Richard Wolf GmbH, Coloplast A/S, Biolitec AG, BVM Medical, Convergent Laser Technologies, Cook Medical, GreenLight Technologies, PROCEPT BioRobotics, Quanta System

Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Trends and Insights

Major companies operating in the benign prostatic hyperplasia (BPH) treatment devices and equipment market are focusing on developing innovative, minimally invasive solutions such as temporarily implantable devices that expand access to outpatient treatment and reduce reliance on long-term medication or tissue-removal procedures. Temporarily implantable BPH devices are single-use or short-term implants designed to reshape the prostatic urethra and relieve lower urinary tract symptoms (LUTS) caused by an enlarged prostate. For instance, in February 2025, Olympus, a japan-based medical technology company, announced a milestone for its iTind device with expanded availability across major APAC markets (Thailand, Australia, Hong Kong, Singapore, India and a planned launch in Korea), highlighting that the iTind procedure is a minimally invasive, clinic-room option that can be performed under local anaesthesia and supported by a comprehensive physician training programme to aid clinical adoption. The iTind is a temporarily implantable nitinol device that reshapes the prostatic urethra to improve urinary flow and patient quality of life, and recent guideline and reimbursement developments are helping accelerate its adoption.

What Are Latest Mergers And Acquisitions In The Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market?

In October 2023, Laborie Medical Technologies Corp., a US-based medical technology company, acquired Urotronic Inc. for an undisclosed amount. This acquisition strengthens Laborie’s therapeutic urology portfolio by integrating Urotronic’s Optilume drug-coated balloon technology for minimally invasive treatment of urethral strictures and benign prostatic hyperplasia (BPH). It further enhances Laborie’s global presence by improving patient access to advanced, evidence-based urologic treatment options and expanding its portfolio of innovative interventional solutions. Urotronic Inc. is a US-based medical equipment manufacturer offering benign prostatic hyperplasia (BPH) treatment devices and equipment.

Regional Outlook

North America was the largest region in the benign prostatic hyperplasia (BPH) treatment devices and equipment market in 2025. Western Europe was the second-largest region in the global benign prostatic hyperplasia (BPH) treatment devices and equipment market. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.

What Defines the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market?

The benign prostatic hyperplasia (BPH) treatment devices and equipment market consist of sales of prostatic stents, catheter ablation devices, resectoscopes, radiofrequency ablation devices, urology lasers, and prostatic stents that are used to treat benign prostatic hyperplasia. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.